Twist Bioscience Corp stock reached a significant milestone, hitting a 52-week high of $106.58. The stock currently trades at $103.80, just shy of its recent peak of $105.47, with a market capitalization of $6.29 billion. This marks a notable achievement for the company, reflecting a robust 267.22% increase over the past year. The impressive year-over-year growth underscores the company’s strong market performance and investor confidence. Yet according to InvestingPro analysis, the stock appears overvalued relative to its Fair Value, with 11 additional ProTips available to subscribers offering deeper insights into TWST’s investment profile. As the stock continues to climb, stakeholders are closely monitoring its trajectory amidst a dynamic market environment.
In other recent news, Twist Bioscience reported its fiscal third-quarter 2026 revenue, which exceeded Wall Street’s expectations. The company achieved revenue of $118.4 million, surpassing the estimated $114.54 million. This marks a 23% increase from the previous year and continues a trend of 14 consecutive quarters of sequential revenue growth. However, the adjusted earnings showed a loss of $0.56 per share, which was wider than the anticipated loss of $0.48 per share. Despite the revenue beat, the focus appears to be on the earnings miss and the company’s journey toward profitability. These developments highlight the mixed financial performance of Twist Bioscience, reflecting both achievements in revenue and challenges in earnings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Is TWST undervalued—or a trap?
Gut instinct isn't enough. Our Fair Value calculator uses 17 proven valuation models to reveal what TWST is really worth.
Get instant clarity on TWST—plus thousands of other stocks—before the opportunity disappears.